VIRGINIA RETIREMENT SYSTEMS ET Al Takes $1.03 Million Position in Dianthus Therapeutics, Inc. $DNTH

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 10,600 shares of the company's stock, valued at approximately $1,033,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in Dianthus Therapeutics in the 2nd quarter valued at $27,000. First Horizon Corp acquired a new stake in Dianthus Therapeutics during the 1st quarter valued at $32,000. Caitong International Asset Management Co. Ltd bought a new position in Dianthus Therapeutics during the fourth quarter worth $40,000. EFG International AG bought a new position in Dianthus Therapeutics during the second quarter worth $49,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the third quarter valued at $64,000. 47.53% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, SVP Adam Veness sold 30,000 shares of the company's stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president owned 30,000 shares of the company's stock, valued at approximately $2,424,000. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Simrat Randhawa sold 23,124 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the sale, the executive vice president owned 4,000 shares in the company, valued at $425,640. This represents a 85.25% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 283,678 shares of company stock worth $29,672,400. 3.02% of the stock is owned by company insiders.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $106.20 on Monday. The stock has a market capitalization of $5.81 billion, a P/E ratio of -25.59 and a beta of 1.24. The stock's fifty day moving average is $106.46 and its 200 day moving average is $91.38. Dianthus Therapeutics, Inc. has a 52 week low of $32.22 and a 52 week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. Equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Citigroup started coverage on shares of Dianthus Therapeutics in a research note on Friday, September 4th. They set a "buy" rating and a $156.00 target price for the company. Raymond James Financial reissued a "strong-buy" rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, August 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Wolfe Research reaffirmed an "outperform" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Truist Financial increased their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $129.83.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company's lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.